Acta Scientific Orthopaedics (ISSN: 2581-8635)

Mini Review Volume 6 Issue 7

Cancer Bone Metastasis, Circulation Biomarkers

Da-Yong Lu* and Bin Xu

School of Life Sciences, Shanghai University, Shanghai, PRC

*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, PRC.

Received: April 19, 2023; Published: June 16, 2023


Cancer bone metastasis was common for cancers. It is very painful for patients. Drug treatment needs to improve for both growth inhibition and symptom management. To promote therapeutic paradigms, clinical drug treatment should be specified. This editorial discusses bone cancer metastasis treatment in personalized medicine.

Keywords:Bone Cancer; Neoplasm Metastasis; Drug Treatment; Clinical Trial


  1. Lambert AW., et al. “Emerging biological principles of metastasis”. Cell 168 (2017): 670-691.
  2. Ahmad AS., et al. “Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960”. British Journal of Cancer 112 (2015): 943-947.
  3. Mehlen P and Puisieux A. “Metastasis; a question of life or death”. Nature Reviews Cancer 6 (2006): 449-458
  4. Weidenfeld K and Barkan D. “EMT and stemness in tumor dormacy and outgrowth: Are they intertwined processes?” Frontiers in Oncology 8 (2018): 381.
  5. Lu DY and Xu B. “Bone metastasis treatment, major frontiers”. Acta Scientific Orthopaedics 7 (2021): 1-2.
  6. Hakim BAA. “Benign bone tumors, an overview”. Acta Scientific Orthopaedics10 (2021): 1-2.
  7. Lu DY and Xu B. “Bone cancer and metastatic trials, drug treatment”. Acta Scientific Orthopaedics9 (2021): 31-33.
  8. Lu DY., et al. “Cancer Metastasis treatments”. Current Drug Therapy1 (2013): 24-29.
  9. Bhadresha KP., et al. “A predictive biomarker panel for bone metastasis, liquid biopsy approach”. Journal of Bone Oncology 29 (2021): 100371.
  10. Lu DY and Xu B. “Cancer bone metastasis, experimental study”. Acta Scientific Orthopeadics 5.12 (2022): 1-3.
  11. Lu DY., et al. “Anti-metastatic drug development, work out towards new direction”. Medicinal Chemistry7 (2018): 512 (192-196).
  12. Lu DY., et al. “Anticancer drug sensitivity testing, a historical review and future perspectives”. Current Drug Therapy1 (2015): 44-55.
  13. Volm M and Efferth T. “Prediction of cancer drug resistance and implications for personalized medicine”. Frontiers in Oncology (2015): 282.
  14. Lu DY and Lu TR. “Drug sensitivity testing, a unique drug selection strategy”. Advances in Biomarker Sciences and Technology 2 (2020): 59-66.
  15. Montero J., et al. “Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy”. Cell 160 (2020): 977-989.
  16. Popova AA and Levkin PA. “Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy”. Advance Therapeutics (2020): 1900100.
  17. Zhang Y., et al. “Anticancer drug sensitivity assay with quantitative heterogeneity testing using single-cell Raman Spectroscope”. Molecules 11 (2018): 2903.
  18. Wang JK., et al. “In vitro anticancer drug sensitivity sensing through single-cell Raman Spectroscopy”. Biosensors8 (2021): 286.
  19. Hammoud MK., et al. “Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level”. Scientific Reports 8 (2018): 15278.
  20. Jelgersma C and Vajkoczy P. “How to target spinal metastasis in experimental research: An overview of currently used experimental mouse model and future prospects”. International Journal of Molecular Sciences 11 (2018): 5420.
  21. Pantano F., et al. “Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions”. Oncogene 40 (2021): 1284-1299.
  22. Lu DY and Che JY. “Bone disease treatments, importance of technical supports”. Acta Scientific Orthopaedics 4 (2021): 55-57.
  23. Lu DY and Lu TR. “Antimetastatic activities and mechanisms of bisdioxopiperazine compound”. Anti-Cancer Agent Medicinal Chemistry7 (2010): 564-570.
  24. Zhu H., et al. “DJ-1 mediates the resistance of cancer cells to dihydroarteminisinin through cancer cells through reactive oxygen species removal”. Free Radical Biology and Medicine 71 (2014): 121-132.
  25. Lu DY., et al. “Development of antimetastatic drugs by targeting tumor sialic acids”. Scientia Pharmaceutica3 (2012): 497-508.
  26. Eslami-SZ., et al. “Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade”. British Journal of Cancer (2017): 10.
  27. Pantel K and Alix-Panabieres C. “Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation”. The Journal for Immunotherapy of Cancer 10 (2022): e005615.
  28. Lu DY., et al. “Drug sensitivity testing for cancer therapy, key areas”. Reviews on Recent Clinical Trials 4 (2022): 291-299.
  29. Agarwal N., et al. “Natural herbs as anticancer drugs”. International Journal of PharmTech Research 3 (2012): 1142-1153.
  30. Lu DY., et al. “Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug”. Studies in Natural Products Chemistry 66 (2020): 91-115.
  31. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice Palliative Medicine International Journal4 (2019): 125-130.
  32. Lu DY., et al. “Cancer bioinformatics for update anticancer drug developments and personalized therapeutics”. Reviews on Recent Clinical Trials2 (2017): 101-110.
  33. Lu DY., et al. “Pharmacogenetics of cancer therapy: breakthroughs from beyond?” Future Science OA4 (2015): FSO.15, 80.
  34. Hyman DH., et al. “Implementing genome-driven oncology”. Cell 168 (2017): 584-599.
  35. Lu DY., et al. “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment”. Medical Hypotheses1 (2006): 45-51.
  36. Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics”. 2014, Woodhead Publishing, Elsevier, UK (2014).
  37. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine 2 (2018): 156-163.
  38. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anticancer Agents Med Chem1 (2017): 21-28.
  39. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials. 12.3 (2017): 202-211.
  40. Barani M., et al. “Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma”. Biosensors 11 (2021): 55.


Citation: Da-Yong Lu and Bin Xu. “Cancer Bone Metastasis, Circulation Biomarkers”.Acta Scientific Orthopaedics 6.7 (2023): 35-37.


Copyright: © 2023 Da-Yong Lu and Bin Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US